Evidence map›Paper›PMID 37794409›Full record

ArticleJournal of neuroinflammation2023

Distinct features of B cell receptors in neuromyelitis optica spectrum disorder among CNS inflammatory demyelinating diseases.

Hyo Jae Kim, Jong-Eun Park, Wangyong Shin, Dayoung Seo, Seungmi Kim, Hyunji Kim, Jinsung Noh, Yonghee Lee, Hyunjin Kim, Young-Min Lim and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroinflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Hyo Jae KimGraduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, South Korea.
Jong-Eun ParkGraduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, South Korea.
Wangyong ShinDepartment of Medicine, Asan Medical Institute of Convergence Science and Technology, University of Ulsan College of Medicine, Seoul, South Korea.
Dayoung SeoDepartment of Medicine, Asan Medical Institute of Convergence Science and Technology, University of Ulsan College of Medicine, Seoul, South Korea.
Seungmi KimDepartment of Medicine, Asan Medical Institute of Convergence Science and Technology, University of Ulsan College of Medicine, Seoul, South Korea.
Hyunji KimDepartment of Medicine, Asan Medical Institute of Convergence Science and Technology, University of Ulsan College of Medicine, Seoul, South Korea.
Jinsung NohBio-MAX Institute, Seoul National University, Seoul, South Korea.
Yonghee LeeDepartment of Electrical and Computer Engineering, Seoul National University, Seoul, South Korea.
Hyunjin KimDepartment of Neurology, Asan Medical Center, Ulsan University of Medicine, Seoul, South Korea.
Young-Min LimDepartment of Neurology, Asan Medical Center, Ulsan University of Medicine, Seoul, South Korea.
Hyori KimConvergence Medicine Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, South Korea. hyol409@gmail.com.
Eun-Jae LeeDepartment of Medicine, Asan Medical Institute of Convergence Science and Technology, University of Ulsan College of Medicine, Seoul, South Korea. siverash@gmail.com.
University of Ulsan · KRKorea Advanced Institute of Science and Technology · KRAsan Medical Center · KRSeoul National University · KRUlsan College · KR

Funding

Asan Institute for Life Sciences, Asan Medical Center 2022IF0019Asan Institute for Life Sciences, Asan Medical Center,South Korea 2019IP0853-1Korea Health Industry Development Institute HR18C0016Korea Health Industry Development Institute,South Korea HI22C0553Korea Health Industry Development Institute,South Korea HR21C0198National Research Foundation of Korea 2023R1A2C2007798
6 · The paper itself

Abstract

backgroundNeuromyelitis optica spectrum disorder (NMOSD) stands out among CNS inflammatory demyelinating diseases (CIDDs) due to its unique disease characteristics, including severe clinical attacks with extensive lesions and its association with systemic autoimmune diseases. We aimed to investigate whether characteristics of B cell receptors (BCRs) differ between NMOSD and other CIDDs using high-throughput sequencing.

methodsFrom a prospective cohort, we recruited patients with CIDDs and categorized them based on the presence and type of autoantibodies: NMOSD with anti-aquaporin-4 antibodies, myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) with anti-myelin oligodendrocyte glycoprotein antibodies, double-seronegative demyelinating disease (DSN), and healthy controls (HCs). The BCR features, including isotype class, clonality, somatic hypermutation (SHM), and the third complementarity-determining region (CDR3) length, were analyzed and compared among the different disease groups.

resultsBlood samples from 33 patients with CIDDs (13 NMOSD, 12 MOGAD, and 8 DSN) and 34 HCs were investigated for BCR sequencing. Patients with NMOSD tended to have more activated BCR features compare to the other disease groups. They showed a lower proportion of unswitched isotypes (IgM and IgD) and a higher proportion of switched isotypes (IgG), increased clonality of BCRs, higher rates of SHM, and shorter lengths of CDR3. Notably, advanced age was identified as a clinical factor associated with these activated BCR features, including increased levels of clonality and SHM rates in the NMOSD group. Conversely, no such clinical factors were found to be associated with activated BCR features in the other CIDD groups.

conclusionsNMOSD patients, among those with CIDDs, displayed the most pronounced B cell activation, characterized by higher levels of isotype class switching, clonality, SHM rates, and shorter CDR3 lengths. These findings suggest that B cell-mediated humoral immune responses and characteristics in NMOSD patients are distinct from those observed in the other CIDDs, including MOGAD. Age was identified as a clinical factor associated with BCR activation specifically in NMOSD, implying the significance of persistent B cell activation attributed to anti-aquaporin-4 antibodies, even in the absence of clinical relapses throughout an individual's lifetime.

Indexed as

Neuromyelitis OpticaAquaporin 4AutoantibodiesHumansMyelin-Oligodendrocyte GlycoproteinProspective StudiesReceptors, Antigen, B-CellAquaporin 4AutoantibodiesMyelin-Oligodendrocyte GlycoproteinReceptors, Antigen, B-CellB cellB cell receptorInflammatory demyelinating disease of the CNSMyelin oligodendrocyte glycoprotein antibody associated diseaseNeuromyelitis optica spectrum disorder

Identifiers

PMID37794409
PMCPMC10548735
OpenAlexW4387339896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.